Aberg-Wistedt A, Alvariza M, Bertilsson L, Malmgren R, Wachtmeister H
Acta Psychiatr Scand. 1985 Mar;71(3):256-68. doi: 10.1111/j.1600-0447.1985.tb01282.x.
Clinical and biochemical effects of two selective 5-HT uptake inhibitors, zimeldine and alaproclate, were studied in 24 hospitalized patients with endogenous depression. According to a randomized parallel group design 14 patients were treated with zimeldine and 10 with alaproclate. The dosage of both zimeldine and alaproclate was 200 mg daily. For the evaluation of the clinical effect, Montgomery & Asberg Depression Rating Scale (MADRS) was used. Seven of 14 patients treated with zimeldine and seven of 10 treated with alaproclate improved. 5-HT uptake inhibition in patients' platelets and concentration of amine metabolites (5-HIAA, HVA, HMPG) in CSF were studied before and during treatment. After 3 weeks of treatment with zimeldine 5-HIAA and HMPG in CSF decreased significantly while HVA in CSF increased significantly. Zimeldine produced a significant 5-HT uptake inhibition in platelets. During treatment with alaproclate no significant change in amine metabolites concentration in CSF was found and there were no mean changes on 5-HT uptake inhibition in platelets.
在24名住院的内源性抑郁症患者中研究了两种选择性5-羟色胺摄取抑制剂齐美利定和阿扑氯丙嗪的临床和生化效应。根据随机平行组设计，14名患者接受齐美利定治疗，10名患者接受阿扑氯丙嗪治疗。齐美利定和阿扑氯丙嗪的剂量均为每日200毫克。为评估临床疗效，使用了蒙哥马利和阿斯伯格抑郁评定量表（MADRS）。接受齐美利定治疗的14名患者中有7名病情改善，接受阿扑氯丙嗪治疗的10名患者中有7名病情改善。在治疗前和治疗期间研究了患者血小板中的5-羟色胺摄取抑制以及脑脊液中胺代谢产物（5-羟吲哚乙酸、高香草酸、3-甲氧基-4-羟基苯乙二醇）的浓度。用齐美利定治疗3周后，脑脊液中的5-羟吲哚乙酸和3-甲氧基-4-羟基苯乙二醇显著降低，而脑脊液中的高香草酸显著增加。齐美利定在血小板中产生了显著的5-羟色胺摄取抑制作用。在使用阿扑氯丙嗪治疗期间，未发现脑脊液中胺代谢产物浓度有显著变化，血小板中5-羟色胺摄取抑制也无平均变化。
